English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the discovery of the novel neurotrophic factor GDNF in 1993 [25], the molecule has received a great deal of attention from neuroscientists studying all aspects of neurotrophic factor physiology and pharmacology. GDNF instantly became a focus of basic research when it was discovered that GDNF was a potent neurotrophic factor for at least two diverse neuronal populations including dopaminergic neurons and motor neurons [25,47] magnitude. A comprehensive review of the pharmacology of GDNF and hypotheses concerning its possible clinical uses is presented. Based upon our current knowledge of GDNF's pharmacology, it appears that the molecule may be useful in the treatment of neurodegenerative diseases, such as Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), other motor neuron diseases (MND) and cholinergic deficit-related dementia.

Therapeutic Potentials for Glial Cell Line-Derived Neurotrophic Factor (GDNF) Based upon Pharmacological Activities in the CNS